retatrutide phase 2 trial obesity type 2 diabetes is investigational and is not FDA approved. In TRANSCEND Retatrutide Severe Obesity Trial Shows

For athletes, high-performers, or patients undergoing active treatment protocols whose nutritional demands may temporarily exceed what oral supplementation provides

By week 4 on doses of 4mg and above, participants showed 14.0 to 19.5 point reductions in sweet food desire compared to placebo

If nausea persists, discuss it with your providerthey can adjust your dose timing or recommend short-term anti-nausea support

However, its important to note: Weight management can be a valuable secondary outcome for people with T2DM, as it often improves insulin sensitivity, lowers cardiovascular risk, and enhances overall metabolic health 4 , 10

Understanding whether combination therapy or monotherapy suits your individual biology requires more than clinical guidelines alone